QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,656 signal articles · 534 in last 24h · 105,348 total before filter · latest 16m ago
534last 24h
2502last 7d
489● bullish (7d)
260● bearish (7d)
200publishers
AllMacro171Earnings1533M&A138Regulatory14Product8Analyst25
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Roth Capital Upgrades ConocoPhillips (COP) to Buy. Here is Why
Insider Monkey42d agobullish
Roth Capital Upgrades ConocoPhillips (COP) to Buy. Here is Why

With an annual dividend yield of 3.00%, ConocoPhillips (NYSE:COP) is included among the 12 Best S&P 500 Stocks to Buy for Dividends. ConocoPhillips (NYSE:COP) is one of the world’s largest independent E&P companies based on oil and natural gas production and proved reserves. On June 22, Roth Capital upgraded ConocoPhillips (NYSE:COP) from ‘Neutral’ to ‘Buy’ and […]

SanDisk Has Run Hot, The Price Target Carries a Warning
24/7 Wall St.42d agoneutral
SanDisk Has Run Hot, The Price Target Carries a Warning

Our 24/7 Wall St. price target for SanDisk (NASDAQ:SNDK) is $1,755.72, which sits roughly 22.78% below where the stock trades today. After a 857.84% year-to-date run, the NAND maker has lapped almost every analyst on the Street, and our proprietary model now signals that risk and reward have inverted. Our recommendation is sell, with high ... SanDisk Has Run Hot, The Price Target Carries a Warning

Brookfield Corp. (BN) Upgraded to Buy: Here's Why
Zacks43d agobullish
Brookfield Corp. (BN) Upgraded to Buy: Here's Why

Brookfield Corp. (BN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Just Supersized Its Price Target on AMD. Is the Stock Still Too Cheap?
24/7 Wall St.43d agoneutral
Wall Street Just Supersized Its Price Target on AMD. Is the Stock Still Too Cheap?

Shares of Advanced Micro Devices (NASDAQ:AMD) traded near $521 midmorning Wednesday, roughly flat on the session after a prior close near $520. The quiet tape masks a loud catalyst: UBS just supersized its price target on AMD stock to $670 from $455, one of the more aggressive upward revisions on the Street this month. The ... Wall Street Just Supersized Its Price Target on AMD. Is the Stock Still Too Cheap?

Another Strategist Raised Their S&P 500 Price Target
Barrons.com43d agoneutral
Another Strategist Raised Their S&P 500 Price Target

The stock market may have hit a wall, but the S&P 500 price targets keep going higher. The strategists at J.P. Morgan were the latest to raise their target: Dubravko Lakos-Bujas of J.P. Morgan wrote in a note Wednesday that he and his team were upping their year-end target to 7800 from 7600. The S&P 500 was up 0.2% to about 7383 on Wednesday.

Salesforce (CRM) Gets Buy Upgrade as AI Concerns Create Compelling Entry Point
Insider Monkey43d agobullish
Salesforce (CRM) Gets Buy Upgrade as AI Concerns Create Compelling Entry Point

Salesforce, Inc. (NYSE:CRM) is one of the 15 AI Stocks Analysts Are Watching: Microsoft, Nvidia, and More. One AI stock Wall Street is bullish on based on its depressed valuation, attractive margin profile, and robust cash flow is Salesforce, Inc. (NYSE:CRM). On June 18, Monness, Crespi, Hardt analyst Brian White upgraded the stock to “Buy” […]

International Business Machines (IBM) Upgraded by JPMorgan as Software Growth Boosts Outlook
Insider Monkey43d agobullish
International Business Machines (IBM) Upgraded by JPMorgan as Software Growth Boosts Outlook

International Business Machines Corporation (NYSE:IBM) is one of the 15 AI Stocks Analysts Are Watching: Microsoft, Nvidia, and More. On June 23, JPMorgan upgraded International Business Machines Corporation (NYSE:IBM) to Overweight from neutral and hiked its price target to $291 from $270. The firm said it sees “software acceleration” for the stock and that there […]

Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update
Insider Monkey43d agoneutral
Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Mizuho analyst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on […]

Monness Crespi Upgrades Salesforce (CRM) to Buy, Here’s Why
Insider Monkey43d agobullish
Monness Crespi Upgrades Salesforce (CRM) to Buy, Here’s Why

Salesforce, Inc. (NYSE:CRM) is one of the best big tech stocks to buy according to Wall Street analysts. Salesforce, Inc. (NYSE:CRM) was upgraded by Monness Crespi to Buy from Neutral on June 18, with the firm setting a price target of $200. It stated that with a 41% decline, the company has “earned the unflattering title […]

Berenberg Downgrades Nutrien (NTR) to Hold – Here’s Why
Insider Monkey43d agobearish
Berenberg Downgrades Nutrien (NTR) to Hold – Here’s Why

Nutrien Ltd. (NYSE:NTR) is one of the top cheap growth stocks to get rich. Berenberg downgraded Nutrien Ltd. (NYSE:NTR) to Hold from Buy on June 10 and adjusted the price target on the stock to $65, up from $61. It told investors in a research note that the company is likely to deliver another year of […]

Deutsche Bank Maintains a Sell Rating on Intuitive Surgical (ISRG), Here’s Why
Insider Monkey43d agobearish
Deutsche Bank Maintains a Sell Rating on Intuitive Surgical (ISRG), Here’s Why

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the top high-conviction stocks to buy according to hedge funds. Deutsche Bank cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 on June 2 while maintaining a Sell rating on the shares. The stock also received a rating update from BofA on May 12, […]

AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal
Simply Wall St.43d agoneutral
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal

AbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the proposed Apogee Therapeutics acquisition. Research around the US$10.9b deal points to a split view, with some analysts highlighting the immunology and atopic dermatitis opportunity, while others question how much value the company can capture against rising competition. As you read on, you will see how these mixed signals are shaping the evolving AbbVie story and what...

International Business Machines (IBM) Soars on New Analyst Upgrade
Insider Monkey43d agobullish
International Business Machines (IBM) Soars on New Analyst Upgrade

International Business Machines Corp. (NYSE:IBM) is one of the 10 Resilient Stocks Beating Market Slump. International Business Machines saw its share prices climb by 5.04 percent on Tuesday to close at $264.94 apiece, after JPMorgan turned bullish for its stock, thanks to the rosy prospects for its software business. In a market note, JPMorgan upgraded […]

Bank of America strongly resets Micron stock price target
TheStreet43d agoneutral
Bank of America strongly resets Micron stock price target

I've covered Micron repeatedly, and each time, the story has been some version of the same thing. The artificial intelligence (AI) memory supercycle is getting bigger than the market expected, and Micron keeps proving the bears wrong. Tuesday, June 23, is a jarring interruption. MU dropped more ...

Does Axon’s Upgraded Outlook and AI Push Reshape The Bull Case For Axon Enterprise (AXON)?
Simply Wall St.43d agobullish
Does Axon’s Upgraded Outlook and AI Push Reshape The Bull Case For Axon Enterprise (AXON)?

Axon Enterprise recently reported strong Q1 2026 results, raised its full-year revenue outlook, and continued winning long-term public safety contracts while facing local political controversy in Scottsdale over a proposed development project. The company is rapidly building an AI-powered public safety platform, spanning TASER 10, Axon Body 4, counter-drone systems, and tools like Axon Assistant and Axon Vision, that aims to lock in agencies through integrated hardware, software, and cloud...

Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
Insider Monkey43d agoneutral
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)

Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks. On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an “Equal Weight” rating on the shares. Separately, Schrödinger, Inc. (NASDAQ:SDGR) maintained full-year guidance for ACV of $218 million to $228 million. The corporation expects 10% to […]

Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Insider Monkey43d agoneutral
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)

Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]